Tegretol XR (carbamazepine) Disease Interactions

There are 6 disease interactions with Tegretol XR (carbamazepine):

The use of carbamazepine has been associated with hematologic toxicities such as leukopenia, neutropenia, thrombocytopenia and, rarely, aplastic anemia and agranulocytosis. Therapy with carbamazepine should be administered with extreme caution in patients with preexisting blood dyscrasias and/or bone marrow depression. Complete blood counts, including platelets and possibly reticulocytes and serum iron, should be performed prior to initiating therapy and regularly during therapy. Patients who exhibit decreases in blood counts at any time during treatment should be monitored more closely. Marked depression of blood counts may be indication for permanent withdrawal of carbamazepine therapy.

Carbamazepine is structurally related to the tricyclic antidepressants (TCAs) and may demonstrate some of the same cardiovascular effects. Specifically, carbamazepine has occasionally caused congestive heart failure, edema, aggravation of hypertension, hypotension, syncope and collapse, aggravation of coronary artery disease, arrhythmias, AV block, thrombophlebitis, and thromboembolism. Myocardial infarction has been associated with TCAs. Therapy with carbamazepine should be considered and administered cautiously in patients with a history of cardiovascular disease or cardiac damage.

Carbamazepine is primarily metabolized by the liver. Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity. Therapy with carbamazepine should be administered cautiously in patients with impaired hepatic function. Caution is also advised when treating patients with a history of liver disease, since the use of anticonvulsants, including carbamazepine, has been associated with hepatotoxicity. Baseline and periodic evaluation of liver function is recommended. Carbamazepine therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.

Carbamazepine is structurally related to the tricyclic antidepressants and has shown mild anticholinergic activity. Therapy with carbamazepine should be administered cautiously in patients with conditions that may be exacerbated by anticholinergic activity, such as urinary retention or obstruction and elevated intraocular pressure, especially angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma.

Carbamazepine is structurally related to the tricyclic antidepressants (TCAs). The possibility of activation of a latent psychosis or exacerbation of psychotic symptoms, especially in elderly patients, should be borne in mind.

Decreased values for thyroid function tests have been observed with carbamazepine administration. One study reported decreased serum levels of T4, FT4, and T3. In that study, TSH concentrations were not significantly altered. Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.

You should also know about...

Tegretol XR (carbamazepine) drug Interactions

There are 840 drug interactions with Tegretol XR (carbamazepine)

Tegretol XR (carbamazepine) food/lifestyle Interactions

There are 2 food/lifestyle interactions with Tegretol XR (carbamazepine)

See also...

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2009 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.